IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 14 NO 3 SEPTEMBER 1997

ISSN 0790-9667

https://doi.org/10.1017/S0790966700003128 Published online by Cambridge University Press



Prescribing Information: XANAX

Presentation: White, oval, biconvex tablet containing 250 micrograms (0.25mg) alprazolam, scored on one side and marked 'UPJOHN 29' on the other. Pink, oval, biconvex tablet containing 500 micrograms (0.5mg) alprazolam, scored on one side and marked 'UPJOHN 55' on the other. Lavender, oval, biconvex tablet containing 1mg alprazolam, scored on one side and marked 'UPJOHN 90' on the other. **Uses:** Xanax is indicated for the treatment of anxiety neuroses, reactive (neurotic) depression, and mixed anxiety depression, also any of the foregoing associated with other diseases such as the chronic phase of alcohol withdrawal. Xanax is also effective for the blocking or attenuation of panic attacks in patients with and without phobic avoidance. **Dosage and administration:** Adults only. Optimum dosage of Xanax is based upon the severity of the symptoms and the individual patient response. *Anxiety* – 0.25mg to 0.5mg three times daily, increasing if required to a total of 3mg daily. *Reactive Neurotic Depression:* 0.5mg three times daily increasing if required to a total of 4mg daily. *Geriatric Patients or in the presence of debilitating disease:* 0.25mg two to three times daily to be gradually increased if needed and tolerated. *Panic related disorders:* 0.5 mg to 1 mg given at bedtime. Dosage adjustments should be in increments no greater than 1 mg every three to four days. Additional doses can be added until a t.i.d. or q.i.d. schedule is achieved. **Contra-indications:** Hypersensitivity to benzodiazepines. **Precautions:** May cause drowsiness. Pregnancy and lactation. Concurrent use of CNS depressants should be avoided. The dosage of Xanax should be terminated gradually as abrupt termination may be associated with withdrawal effects. **Side effects:** Mild and transitory. Drowsiness and lightheadedness. Rarely blurred vision, headache, depression, insomnia and gastrointestinal symptoms. **Pharmaceutical precautions:** Protect from light. **GMS price:** 0.25mg x 100 tabs, £5.02, 0.5mg x 100 tabs, £9.65, 1.0mg x 100 tabs, £20.13. **Product Authorisation Numbers:** 0.25mg x 100 PA 16/37/1, 0.5mg x 100 PA 16/37/2, 1.0mg x 100 PA 16/37/3. **PA Holder:** Upjohn LTD, Davy Avenue, Knowlhill Milton Keynes, MK5 8PH. Distributed in Ireland by Pharmacia & Upjohn, Airways Industrial Estate, Cloghran, Dublin 17.

Further information is available on request from Pharmacia & Upjohn, Airways Industrial Estate, Cloghran, Dublin 17. June 1996. Legal Category: SIA.

Pharmacia & Upjohn

PO Box 1752, Airways Industrial Estate, Dublin 17, Ireland
Telephone Nat 01 842 8733
Int +353 1 8428733
Facsimile Nat 01 842 8936
Int +353 1 842 8936
Registered in Ireland No. 168602

https://doi.org/10.1017/S0790966700003128 Published online by Cambridge University Press

Xan1/AB/896

The mundane can seem extraordinary when viewed differently, as in the above Scanning Electron Micrograph (130 x enlargement) of an insect's head

Submissions & correspondence to:
The Editor,
Irish Journal of Psychological Medicine,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.

Telephone
01-2803967; Int: +353-1-2803967

Fax
01-2807076; Int: +353-1-2807076

Publisher
MedMedia Ltd.
Media House,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.

Printing: New Cityview Press

Subscriptions
Rates per volume of four issues (Mar, Jun, Sept, Dec)
STG£43 EU, US$96 USA, STG£53 elsewhere (single issues US$28 USA, STG£13.25 elsewhere) incl. airmail postage internationally.

Subscription enquiries, orders and cheques made payable to:
Royal Society of Medicine Press Ltd.,
1 Wimpole St,
London, W1M 8AE, UK.
Tel: 0171-2902927;
int: +44-171-2902927.
Fax: 0171-2902929;
int: +44-171-2902929.

Circulation
3,000 to 54 countries.
Journal participates in the World Health Organisation project to improve distribution of scientific materials on mental health.

IRISH JOURNAL OF **PSYCHOLOGICAL MEDICINE**

VOL 14 NO 3 SEPTEMBER 1997 ISSN 0790-9667

Cover illustration: 'The Lustre Jug', Walter Osbourne *(1859-1903)*

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from **University Microfilms International**, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the **Adonis** service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in **Ulrich's** International Periodicals Directory (**Bowker** International Serials Database), **EBSCO's** Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

https://doi.org/10.1017/S0790966700003128 Published online by Cambridge University Press

Fast Response

Can start to improve symptoms within seven days

FIRST CHOICE

LUSTRAL™ 50mg

sertraline

A first choice antidepressant

Abbreviated Prescribing Information: LUSTRAL™ (sertraline)
Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). **Dosage:** Lustral should be given as a single daily dose. The initial dose is 50mg and the usual antidepressant dose is 50mg. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. **Use in children:** Not recommended. **Use in elderly:** Usual adult dose. **Contra-indications:** Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not use with, or within two weeks of ending treatment with MAOI's. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquillizers in patients who drive or operate machinery. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs such as tryptophan or fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somnolence, headache and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no casual relationship: movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea and rash. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. As with all psychoactive medicines, possible side effects on discontinuation, such as dizziness, sensory disturbance, sleep disturbance, agitation or anxiety, nausea and sweating. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 822/1/4) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. **Product Authorisation Holder:** Pfizer (Ireland) Limited, Pharmapark, Chapelizod, Dublin 20, Republic of Ireland. **Further information on request:** Pfizer (Ireland) Limited. Date last revised: 1/11/96
66973 June 97